These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 19888523)

  • 41. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
    de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
    Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism.
    Bernardi E; Prandoni P
    Curr Opin Pulm Med; 2005 Sep; 11(5):363-7. PubMed ID: 16093806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II.
    Spirk D; Ugi J; Korte W; Husmann M; Hayoz D; Baldi T; Frauchiger B; Banyai M; Aujesky D; Baumgartner I; Kucher N
    Thromb Haemost; 2011 Jun; 105(6):962-7. PubMed ID: 21475778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?].
    Scharf RE
    Dtsch Med Wochenschr; 2011 Nov; 136(47):2403. PubMed ID: 22094968
    [No Abstract]   [Full Text] [Related]  

  • 46. Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?
    Qayyum F; Holbrook A; Lam J; Kovacs MJ; Schulman S
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):705-13. PubMed ID: 23080362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
    Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
    Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemorrhagic complications of anticoagulant therapy.
    Levine MN; Hirsh J
    Semin Thromb Hemost; 1986 Jan; 12(1):39-57. PubMed ID: 3515558
    [No Abstract]   [Full Text] [Related]  

  • 49. Aspects of anticoagulation in children.
    Payne JH
    Br J Haematol; 2010 Aug; 150(3):259-77. PubMed ID: 20528873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
    Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
    Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit.
    Rodger M; Carrier M; Gandara E; Le Gal G
    Blood Rev; 2010; 24(4-5):171-8. PubMed ID: 20633967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Lemaire J; Pineo GF; Baylis B; Ginsberg JS; Panju AA; Brill-Edwards P; Brant R
    Arch Intern Med; 1992 Aug; 152(8):1589-95. PubMed ID: 1497392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of anticoagulants in elderly patients.
    Bauersachs RM
    Thromb Res; 2012 Feb; 129(2):107-15. PubMed ID: 22014849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy.
    Rosenberg AF; Zumberg M; Taylor L; LeClaire A; Harris N
    J Pharm Pract; 2010 Jun; 23(3):210-6. PubMed ID: 21507816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
    Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
    Panminerva Med; 2012 Mar; 54(1):39-44. PubMed ID: 22278115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of heparin therapy: Controlled prospective trial.
    Salzman EW; Deykin D; Shapiro RM; Rosenberg R
    N Engl J Med; 1975 May; 292(20):1046-50. PubMed ID: 1091856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anticoagulation for venous thromboembolism: what if they bleed?
    Palareti G
    Hamostaseologie; 2012; 32(1):40-4. PubMed ID: 22009202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic monitoring of unfractionated heparin - trials and tribulations.
    Baluwala I; Favaloro EJ; Pasalic L
    Expert Rev Hematol; 2017 Jul; 10(7):595-605. PubMed ID: 28632418
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 60. Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis.
    Kearon C; Harrison L; Crowther M; Ginsberg JS
    Thromb Res; 2000 Mar; 97(6):395-403. PubMed ID: 10704648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.